To determine the primary LPA receptor involved in the inhibition of HCC cell viability, we treated HCC cells with pharmacological agents: Ki16425 (a selective antagonist of LPAR1 and LPAR3) and H2L5186303 (a selective inhibitor of LPAR2) and assessed their cell viability. This evidence concerns the gene LPAR2 and hepatocellular carcinoma.